^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Cancer

    Related cancers:
    1d
    RCT of Mobile Apps & FitBit v. Usual Care (clinicaltrials.gov)
    P=N/A, N=107, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Aug 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    1d
    Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma (clinicaltrials.gov)
    P3, N=820, Not yet recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Oct 2025 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • osemitamab (TST001)
    1d
    Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) (clinicaltrials.gov)
    P2, N=39, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    AiTan (rivoceranib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    2d
    JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. (clinicaltrials.gov)
    P3, N=560, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan
    2d
    EsophaCap for the Detection of Early Esophageal Carcinoma (clinicaltrials.gov)
    P=N/A, N=2500, Recruiting, Johns Hopkins University | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    2d
    Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    docetaxel • 5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154)
    2d
    The cancer-testis lncRNA LINC01940 promotes gastric cancer malignant progression and chemoresistance by enhancing ribosome biogenesis via TAF15-mediated NOL11 SUMOylation. (PubMed, Cell Mol Biol Lett)
    LINC01940 is a cancer-testis lncRNA that promotes GC progression and cisplatin resistance by enhancing ribosome biogenesis via the METTL16/IGF2BP3-TAF15-NOL11 axis. These findings suggest its potential as a prognostic biomarker and therapeutic target in GC.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • TAF15 (TATA-Box Binding Protein Associated Factor 15) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • TAF1 (TATA-Box Binding Protein Associated Factor 1) • METTL16 (Methyltransferase 16, RNA N6-Adenosine)
    |
    cisplatin
    2d
    Analysis of clinicopathological and molecular characteristics of EBV-associated gastric cancer. (PubMed, Discov Oncol)
    EBV-GC is characterized by distinct clinicopathological and molecular features. Pathological examination, immunophenotyping, and NGS provide significant value for diagnosis and therapeutic direction.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A)
    |
    TP53 mutation • EGFR mutation • MSI-H/dMMR • PIK3CA mutation • ARID1A mutation
    2d
    GEN001-201: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (clinicaltrials.gov)
    P2, N=42, Completed, Genome & Company | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • GEN-001
    2d
    Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, Roswell Park Cancer Institute | Trial completion date: Mar 2026 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • oxaliplatin • leucovorin calcium • fluorouracil topical
    2d
    Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (clinicaltrials.gov)
    P=N/A, N=420, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    2d
    The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Mayo Clinic
    New P2 trial